// App-Quantinova.ai

904 : Heterozygous ATG7 inhibition enhances endocrine therapy responsiveness through regulation of damage associated molecular patterns and priming the immune system in ER+ breast tumors

Researchers

Presenter

  • Robert Clarke

Principal Investigators

  • Pamela A.G. Clarke

  • Anni Warri

  • Katherine L. Cook

Medical Centers

  • Georgetown University, Washington, DC

  • Wake Forest School of Medicine, Winston-Salem, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • C-C Motif Chemokine Ligand 2

  • C-C Motif Chemokine Ligand 22

  • Cluster of differentiation 8A

  • High Mobility Group Box 1

  • Interleukin 6

Drug/Treatment

  • chloroquine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved